FINWIRES · TerminalLIVE
FINWIRES

HCA医疗保健公司第一季度业绩超出预期;呼吸系统疾病入院人数下降

-- HCA Healthcare (HCA) 第一季度业绩超出市场预期,但这家医院运营商表示,由于呼吸系统疾病活动减少,其入院人数并未出现往常的季节性增长。 该公司周五公布,截至 3 月 31 日的第一季度调整后每股收益为 7.15 美元,高于去年同期的 6.45 美元,也超过了 FactSet 调查的 7.12 美元的预期。营收增长 4.3% 至 191.1 亿美元,高于华尔街预期的 190.9 亿美元。 HCA Healthcare 表示,由于呼吸系统疾病活动减少,其本季度并未出现往常的季节性业务量增长。与呼吸系统疾病相关的入院人数同比下降 42%,而呼吸系统疾病相关的急诊就诊量也下降了 32%。该公司还表示,1 月份的冬季风暴也对某些市场的季度业务量造成了影响。 据该公司称,不利的销量下滑因素基本被某些医疗补助补充计划的确认所抵消,这些计划并未反映在其最初的全年展望中。 HCA Healthcare的股价在周五的交易中下跌了7.4%,使其年初至今的跌幅扩大至7.6%。 “年初对HCA Healthcare而言是一个充满活力的环境,”首席执行官萨姆·哈森在一份声明中表示。 该公司表示,同店入院人数小幅增长0.9%,急诊室就诊量微增0.3%。同店住院手术量下降0.3%,门诊手术量下降1.7%。 该公司继续预测,2026年每股净收入将在29.10美元至31.50美元之间,营收将在765亿美元至800亿美元之间。华尔街预期该公司2026年的每股收益为30.39美元,销售额为786亿美元。

Price: $448.41, Change: $-25.62, Percent Change: -5.40%

Related Articles

Asia

Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies

Clinuvel Pharmaceuticals (ASX:CUV) is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a "totality of evidence" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.

$ASX:CUV
Asia

ASX Preview: Australian Shares Set to Open Flat on Stalled US-Iran Talks; Origin Energy Reports Lower March Quarter Production

Australian shares are set to open flat on Monday, as oil prices climbed almost 2% following stalled US-Iran peace negotiations and restricted flows through the Strait of Hormuz, tightening global supply and pushing Brent crude above $107 a barrel.On April 25, the S&P 500 and the Nasdaq Composite rose 0.8% and 1.6%, respectively, while the Dow Jones Industrial Average fell 0.2%.In the macroeconomy, investors are eyeing the release of Australia's consumer price index report on Wednesday.In corporate news, Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.IperionX's (ASX:IPX) titanium powder production operations in Virginia, US, transitioned to an around-the-clock production schedule during the March quarter, advancing from commissioning to continuous operations, according to a Monday filing with the Australian bourse.Australia's benchmark index fell 0.1% or 6.9 points to close at 8,786.50 on April 24.

$^AXJO$ASX:IPX$ASX:ORG
Asia

Cobre Appoints Chief Financial Officer

Cobre (ASX:CBE) has appointed Kaveen Bachoo as chief financial officer, effective April 28, according to a Monday filing with the Australian bourse.Bachoo has over 20 years of finance leadership experience in the mining sector, including executive positions at Glencore.

$ASX:CBE